News Search Results
Apr 22, 2026, 18:30 ET Prestige Biopharma IDC Files Patent for Next-Generation Antibody Delivery Platform 'IDC224'… Driving Innovation in Subcutaneous (SC) Formulations
patients. Given the high patient convenience and the mitigation of risks associated with repeated vascular access, the global pharmaceutical and biotechnology industry is witnessing a strategic shift from IV to SC delivery methods.However, antibody therapeutics face significant technical barriers
More news about: Prestige Biopharma
Apr 22, 2026, 17:17 ET Tasman Therapeutics to Participate in Needham Virtual Psychedelics Forum on April 27, 2026
Tasman Therapeutics, a biotechnology company developing novel treatments for patients with hard-to-treat mood disorders, announced today that CEO Dan Browne will participate in a panel
More news about: Tasman Therapeutics
Apr 22, 2026, 17:13 ET Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
served as Managing Director, Supervisory and Senior Biotechnology Analyst at JMP Securities, LLC, where he was a founding healthcare partner and launched the firm's biotechnology research franchise.Earlier in his career, Dr. Duncan held biotechnology equity research positions at Dresdner Kleinwort
More news about: Vanda Pharmaceuticals Inc.
Apr 22, 2026, 16:22 ET Hewlett Foundation President: Philanthropy Must Bridge AI Governance Gap Between Washington and Silicon Valley
challenges, the Hewlett Foundation recently announced $10 million in exploratory grants to support the security of emerging technologies, including AI, biotechnology, and quantum computing.Major grants were awarded to Stanford University's Hoover Institution for its Tech Futures Lab, which focuses on anticipating
More news about: The Hewlett Foundation
Apr 22, 2026, 16:00 ET AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Apr 22, 2026, 15:56 ET GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists
Jersey in 2002, GenScript has grown from a pioneering gene synthesis company into a global biotechnology enterprise serving customers in more than 100 countries. Today, GenScript supports researchers, biotechnology innovators, and pharmaceutical companies worldwide through solutions that accelerate discovery,
More news about: GenScript Biotech Corporation
Apr 22, 2026, 15:26 ET GenScript Leaders Named Entrepreneur Of The Year® 2026 New Jersey Finalists
Jersey in 2002, GenScript has grown from a pioneering gene synthesis company into a global biotechnology enterprise serving customers in more than 100 countries. Today, GenScript supports researchers, biotechnology innovators, and pharmaceutical companies worldwide through solutions that accelerate discovery,
More news about: GenScript Biotech Corporation
Apr 22, 2026, 12:22 ET Pendulum, the Breakthrough Gut Health Brand, Launches Nationwide at Sprouts Farmers Market
type 2 diabetes. Perraudeau et al 2020 doi: 10.1136/bmjdrc-2020-001319About Pendulum TherapeuticsPendulum Therapeutics is a biotechnology company pioneering next-generation microbiome innovations designed to improve human health. Founded in 2012 by a team of scientists from Harvard,
More news about: Pendulum Therapeutics
Apr 22, 2026, 11:57 ET Global Cloud ELN Service Market | USA, China, India Lead | Thermo Fisher Scientific, Agilent Technologies, Dassault Systèmes Drive Digital Lab Transformation
costsAI-Integrated ELNs are gaining traction for predictive insights and faster experimentationAdoption is expanding across pharmaceuticals, biotechnology, chemicals, and materials science, where secure and efficient data handling is mission-critical.Speak to Analyst: Customize insights
More news about: Future Market Insights
Apr 22, 2026, 11:22 ET Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
Apr 22, 2026, 11:00 ET H.I.G. Capital Announces the Sale of Celerion
integrated suite of services spanning data management, biostatistics, and clinical monitoring that supports a global base of pharmaceutical and biotechnology customers through its purpose-built clinical and laboratory infrastructure with facilities in Lincoln, Phoenix, Zurich, and Belfast.H.I.G.
More news about: H.I.G. Capital
Apr 22, 2026, 10:16 ET Digital Pathology Market to Reach USD 1,791.30 Million by 2030, Growing at 9.3% CAGR: Allied Market Research
principal clinical mandate(offer) of digital pathology systems. Drug Discovery is the most rapidly expanding application where pharmaceutical and biotechnology Companies harness digital platforms for quick biomarker identification, companion diagnostic development, and clinical trial tissue analysis. Rapidly
More news about: Allied Market Research
Apr 22, 2026, 10:01 ET Conductive Textiles Market to Reach US$ 8.5 billion by 2033, Expands Amid Smart Wearables and Advanced Material Innovation - Persistence Market Research
Ozone-Based Systems, Fogging & Electrostatic Sprayers, Others), Form (Wipes, Liquid, Spray), End Use (Healthcare Facilities, Pharmaceutical & Biotechnology, Medical Device Manufacturing, Academics & Research Institutes, Food & Beverage, Transportation, Commercial Buildings), and Regional Analysis
More news about: Persistence Market Research Pvt. Ltd.
Apr 22, 2026, 09:30 ET Made Scientific and Regenicin Announce Manufacturing Relationship to Advance NovaDerm Toward FDA Product Approval
/PRNewswire/ -- Made Scientific, Inc., a U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Regenicin, Inc., a biotechnology company specializing in the development and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs,
More news about: Made Scientific, Inc.
Apr 22, 2026, 09:00 ET Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI
pioneer in AI-enabled target discovery, Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company recently published a comprehensive review that emphasizes key considerations in target selection, summarizes breakthroughs in the application
More news about: Insilico Medicine
Apr 22, 2026, 08:45 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene
More news about: Anixa Biosciences, Inc.
Apr 22, 2026, 08:00 ET Deerfield Group Launches Prismatiq™, an Intuitive Field Enablement Platform Purpose-Built for Life Sciences
GroupDeerfield Group is a full-service integrated marketing, communications, and media agency providing innovative solutions for pharmaceutical, biotechnology, health tech, and consumer health companies. Deerfield's solutions are designed to meet the unique needs of healthcare organizations at all stages
More news about: Deerfield Group
Apr 22, 2026, 08:00 ET Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268
SAN FRANCISCO, April 22, 2026 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and
More news about: Thryv Therapeutics Inc.
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
breast cancer (TNBC)The positive NB data from studies undertaken by Penn State University's Jeremy Hengst and Apogee Biotechnology, and funded by the Beat Childhood Cancer Foundation and Four Diamonds, indicate that opaganib may enhance the therapeutic efficacy of the oxaliplatin
More news about: RedHill Biopharma Ltd.
Apr 22, 2026, 02:50 ET Samsung Biologics Reports First Quarter 2026 Financial Results
capacity and rapid response capabilities. In addition, the company announced a collaboration with Eli Lilly and Company to foster open innovation and biotechnology ecosystem development. These initiatives reflect the company's broader commitment to long-term industry collaboration and sustainable growth.The
More news about: Samsung Biologics
Apr 21, 2026, 21:30 ET Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering
SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced the pricing of its upsized underwritten
More news about: Nektar Therapeutics
Apr 21, 2026, 19:31 ET MAHA ACTION WELCOMES BIOTECH PIONEER LOU REESE TO ITS BOARD OF DIRECTORS
America Healthy Again movement, today announced that Lou Reese has joined its Board of Directors. The appointment brings world-class expertise in biotechnology, global health innovation, and regenerative agriculture to the organization's leadership.
More news about: MAHA Action
Apr 21, 2026, 19:30 ET ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026
SEOUL, South Korea, April 21, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that results from its Phase 2 clinical study of VT-EBV-N have been
More news about: ViGenCell Inc.
Apr 21, 2026, 18:05 ET MEDP INVESTOR DEADLINE: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Medpace is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.The Medpace class action lawsuit alleges that defendants throughout the
More news about: Robbins Geller Rudman & Dowd LLP
Apr 21, 2026, 16:23 ET BioMarin Announces Board Leadership Transition
continue executing our strategy for patients around the world."About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.